Respiratory Medicine, ISSN 0954-6111, 2013, Volume 107, Issue 7, pp. 987 - 1000
Summary Background Beclometasone dipropionate is an inhaled corticosteroid (ICS) available in both extrafine and larger-particle hydrofluoroalkane...
Pulmonary/Respiratory | Beclometasone | Inhaler | Asthma control | Lung deposition | Extrafine particle | APPROXIMATELY HALF | TRIALS | CARDIAC & CARDIOVASCULAR SYSTEMS | HFA-BECLOMETHASONE | EFFICACY | CHLOROFLUOROCARBON BECLOMETHASONE | RATIO | HYDROFLUOROALKANE-134A BECLOMETHASONE DIPROPIONATE | CONTROLLER | RESPIRATORY SYSTEM | VALIDITY | Medication Adherence - statistics & numerical data | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Anti-Asthmatic Agents - therapeutic use | Humans | Middle Aged | Male | Young Adult | Aged, 80 and over | Metered Dose Inhalers | Adult | Female | Retrospective Studies | Beclomethasone - chemistry | Child | Anti-Asthmatic Agents - chemistry | Beclomethasone - administration & dosage | Drug Administration Schedule | Administration, Inhalation | Treatment Outcome | Asthma - drug therapy | Chemistry, Pharmaceutical | Particle Size | Adolescent | Glucocorticoids - chemistry | Aged | Primary Health Care | Anti-Asthmatic Agents - administration & dosage | Beclomethasone - therapeutic use | Beclomethasone dipropionate | Corticosteroids | Comparative analysis | Asthma | Steroids | Population | Chronic obstructive pulmonary disease | Drug therapy | Prescriptions | Data bases
Pulmonary/Respiratory | Beclometasone | Inhaler | Asthma control | Lung deposition | Extrafine particle | APPROXIMATELY HALF | TRIALS | CARDIAC & CARDIOVASCULAR SYSTEMS | HFA-BECLOMETHASONE | EFFICACY | CHLOROFLUOROCARBON BECLOMETHASONE | RATIO | HYDROFLUOROALKANE-134A BECLOMETHASONE DIPROPIONATE | CONTROLLER | RESPIRATORY SYSTEM | VALIDITY | Medication Adherence - statistics & numerical data | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Anti-Asthmatic Agents - therapeutic use | Humans | Middle Aged | Male | Young Adult | Aged, 80 and over | Metered Dose Inhalers | Adult | Female | Retrospective Studies | Beclomethasone - chemistry | Child | Anti-Asthmatic Agents - chemistry | Beclomethasone - administration & dosage | Drug Administration Schedule | Administration, Inhalation | Treatment Outcome | Asthma - drug therapy | Chemistry, Pharmaceutical | Particle Size | Adolescent | Glucocorticoids - chemistry | Aged | Primary Health Care | Anti-Asthmatic Agents - administration & dosage | Beclomethasone - therapeutic use | Beclomethasone dipropionate | Corticosteroids | Comparative analysis | Asthma | Steroids | Population | Chronic obstructive pulmonary disease | Drug therapy | Prescriptions | Data bases
Journal Article
Annals of Hematology, ISSN 0939-5555, 12/2015, Volume 94, Issue 12, pp. 2073 - 2075
Medicine & Public Health | Hematology | Oncology | HEMATOLOGY | CONTROLLED-TRIAL | THERAPY | Hematologic Neoplasms - therapy | Acute Disease | Beclomethasone - administration & dosage | Gastrointestinal Diseases - mortality | Hematologic Neoplasms - mortality | Humans | Middle Aged | Male | Cord Blood Stem Cell Transplantation | Allografts | Graft vs Host Disease - drug therapy | Graft vs Host Disease - mortality | Gastrointestinal Diseases - drug therapy | Aged, 80 and over | Adult | Anti-Inflammatory Agents - administration & dosage | Female | Aged | Beclomethasone dipropionate | Care and treatment | Cross infection | Nosocomial infections | Gastrointestinal system | Steroids
Journal Article
Allergy, ISSN 0105-4538, 01/2006, Volume 61, Issue 1, pp. 72 - 78
Background: Roflumilast is an oral, once-daily phosphodiesterase 4 inhibitor with anti-inflammatory activity in development for the treatment of asthma....
ICS | roflumilast | asthma | PDE4 inhibitor | beclomethasone | Beclomethasone | Roflumilast | Asthma | MONTELUKAST | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | INHALED CORTICOSTEROIDS | IMMUNOLOGY | THERAPY | FLUTICASONE PROPIONATE | ALLERGY | INFLAMMATION | INHIBITORS | Follow-Up Studies | Humans | Middle Aged | Male | Dose-Response Relationship, Drug | Forced Expiratory Volume | Benzamides - administration & dosage | Cyclopropanes - administration & dosage | Statistics, Nonparametric | Adult | Anti-Inflammatory Agents - administration & dosage | Female | Child | Asthma - diagnosis | Severity of Illness Index | Aminopyridines - administration & dosage | Beclomethasone - administration & dosage | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Administration, Oral | Administration, Inhalation | Probability | Treatment Outcome | Asthma - drug therapy | Phosphodiesterase Inhibitors - administration & dosage | Adolescent | Aged | Respiratory Function Tests
ICS | roflumilast | asthma | PDE4 inhibitor | beclomethasone | Beclomethasone | Roflumilast | Asthma | MONTELUKAST | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | INHALED CORTICOSTEROIDS | IMMUNOLOGY | THERAPY | FLUTICASONE PROPIONATE | ALLERGY | INFLAMMATION | INHIBITORS | Follow-Up Studies | Humans | Middle Aged | Male | Dose-Response Relationship, Drug | Forced Expiratory Volume | Benzamides - administration & dosage | Cyclopropanes - administration & dosage | Statistics, Nonparametric | Adult | Anti-Inflammatory Agents - administration & dosage | Female | Child | Asthma - diagnosis | Severity of Illness Index | Aminopyridines - administration & dosage | Beclomethasone - administration & dosage | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Administration, Oral | Administration, Inhalation | Probability | Treatment Outcome | Asthma - drug therapy | Phosphodiesterase Inhibitors - administration & dosage | Adolescent | Aged | Respiratory Function Tests
Journal Article
Journal of Perinatology, ISSN 0743-8346, 02/2017, Volume 37, Issue 2, pp. 197 - 202
OBJECTIVE: The efficacy of inhaled steroids in spontaneously breathing infants with established bronchopulmonary dysplasia (BPD) is debatable. The inhaled...
TRIAL | METERED-DOSE INHALER | DEPOSITION | CHLOROFLUOROCARBON-BECLOMETHASONE | ASTHMA | BUDESONIDE | PEDIATRICS | PRETERM INFANTS | FLUTICASONE | CHRONIC LUNG-DISEASE | HYDROFLUOROALKANE-BECLOMETHASONE | OBSTETRICS & GYNECOLOGY | Beclomethasone - administration & dosage | Glucocorticoids - administration & dosage | Respiration, Artificial - methods | Double-Blind Method | Infant, Very Low Birth Weight | Humans | Administration, Inhalation | Infant | Male | Treatment Outcome | Pilot Projects | Bronchopulmonary Dysplasia - therapy | Female | Infant, Extremely Premature | Israel | Patient Readmission - statistics & numerical data | Infant, Newborn | Length of Stay - statistics & numerical data | Infants (Premature) | Beclomethasone dipropionate | Bronchopulmonary dysplasia | Dosage and administration | Drug therapy | Health aspects | Risk factors
TRIAL | METERED-DOSE INHALER | DEPOSITION | CHLOROFLUOROCARBON-BECLOMETHASONE | ASTHMA | BUDESONIDE | PEDIATRICS | PRETERM INFANTS | FLUTICASONE | CHRONIC LUNG-DISEASE | HYDROFLUOROALKANE-BECLOMETHASONE | OBSTETRICS & GYNECOLOGY | Beclomethasone - administration & dosage | Glucocorticoids - administration & dosage | Respiration, Artificial - methods | Double-Blind Method | Infant, Very Low Birth Weight | Humans | Administration, Inhalation | Infant | Male | Treatment Outcome | Pilot Projects | Bronchopulmonary Dysplasia - therapy | Female | Infant, Extremely Premature | Israel | Patient Readmission - statistics & numerical data | Infant, Newborn | Length of Stay - statistics & numerical data | Infants (Premature) | Beclomethasone dipropionate | Bronchopulmonary dysplasia | Dosage and administration | Drug therapy | Health aspects | Risk factors
Journal Article
Journal of Pharmaceutical and Biomedical Analysis, ISSN 0731-7085, 04/2019, Volume 167, pp. 123 - 131
The present study focuses on identifying the degradation profile and pathways of unknown impurities from beclomethasone dipropionate (BDP) topical cream...
Preparative isolation and characterizations | Beclomethasone dipropionate | ESI-MS | Degradation impurities | Topical cream formulation | HPLC | NMR techniques | CHEMISTRY, ANALYTICAL | QUANTIFICATION | STRUCTURAL-CHARACTERIZATION | MS/MS | PHARMACEUTICAL FORMULATIONS | PLASMA | LIQUID-CHROMATOGRAPHY | PRODUCTS | PHARMACOLOGY & PHARMACY | CORTICOSTEROIDS | Nuclear magnetic resonance spectroscopy | Mass spectrometry | High performance liquid chromatography | Steroids
Preparative isolation and characterizations | Beclomethasone dipropionate | ESI-MS | Degradation impurities | Topical cream formulation | HPLC | NMR techniques | CHEMISTRY, ANALYTICAL | QUANTIFICATION | STRUCTURAL-CHARACTERIZATION | MS/MS | PHARMACEUTICAL FORMULATIONS | PLASMA | LIQUID-CHROMATOGRAPHY | PRODUCTS | PHARMACOLOGY & PHARMACY | CORTICOSTEROIDS | Nuclear magnetic resonance spectroscopy | Mass spectrometry | High performance liquid chromatography | Steroids
Journal Article
Science of the Total Environment, ISSN 0048-9697, 04/2015, Volume 511, pp. 37 - 46
Asthma is commonly treated with inhalable glucocorticosteroids, including beclomethasone dipropionate (BDP). This is a synthetic prodrug which is metabolized...
Beclomethasone dipropionate | Environmental risk assessment | Asthma medicine | Gene expression | Glucocorticoid | Rainbow trout | HUMAN PHARMACEUTICALS | RAINBOW-TROUT | BLOOD-PLASMA | MICROTITER PLATE ASSAY | ENVIRONMENTAL SCIENCES | GLUCOCORTICOID-RECEPTOR | PLASMA-LEVELS | GLUTATHIONE DISULFIDE | TRIPEPTIDYL-PEPTIDASE-II | FATHEAD MINNOW | CORTISOL | Catalase - metabolism | Animals | Water Pollutants, Chemical - toxicity | Glutathione - metabolism | Beclomethasone - toxicity | Glucocorticoids - toxicity | Fishes - physiology | Metabolites | Trout | Blood sugar | Analysis | Fishes | Physiological aspects | Steroids | Human | Drugs | Catalase | Fish | Exposure | Physiology | Glucose | Chemical compounds | Glutathione | Naturvetenskap | Kemi | Natural Sciences | Organisk kemi | Chemical Sciences | thma medicine | Organic Chemistry
Beclomethasone dipropionate | Environmental risk assessment | Asthma medicine | Gene expression | Glucocorticoid | Rainbow trout | HUMAN PHARMACEUTICALS | RAINBOW-TROUT | BLOOD-PLASMA | MICROTITER PLATE ASSAY | ENVIRONMENTAL SCIENCES | GLUCOCORTICOID-RECEPTOR | PLASMA-LEVELS | GLUTATHIONE DISULFIDE | TRIPEPTIDYL-PEPTIDASE-II | FATHEAD MINNOW | CORTISOL | Catalase - metabolism | Animals | Water Pollutants, Chemical - toxicity | Glutathione - metabolism | Beclomethasone - toxicity | Glucocorticoids - toxicity | Fishes - physiology | Metabolites | Trout | Blood sugar | Analysis | Fishes | Physiological aspects | Steroids | Human | Drugs | Catalase | Fish | Exposure | Physiology | Glucose | Chemical compounds | Glutathione | Naturvetenskap | Kemi | Natural Sciences | Organisk kemi | Chemical Sciences | thma medicine | Organic Chemistry
Journal Article
Expert Opinion on Drug Safety, ISSN 1474-0338, 09/2018, Volume 17, Issue 9, pp. 963 - 969
Introduction: Beclomethasone dipropionate (BDP) is a second-generation corticosteroid that uses novel drug technologies to ensure colonic targeting and...
Inflammatory bowel disease | ulcerative colitis | steroids | beclomethasone dipropionate | adverse events | safety | CONTROLLED-TRIAL | SODIUM-PHOSPHATE ENEMAS | ORAL BECLOMETASONE DIPROPIONATE | 5-AMINOSALICYLIC ACID | NETWORK METAANALYSIS | CLINICAL-PRACTICE GUIDELINES | INFLAMMATORY-BOWEL-DISEASE | THERAPEUTIC-EFFICACY | DOUBLE-BLIND | ITALIAN GROUP | PHARMACOLOGY & PHARMACY
Inflammatory bowel disease | ulcerative colitis | steroids | beclomethasone dipropionate | adverse events | safety | CONTROLLED-TRIAL | SODIUM-PHOSPHATE ENEMAS | ORAL BECLOMETASONE DIPROPIONATE | 5-AMINOSALICYLIC ACID | NETWORK METAANALYSIS | CLINICAL-PRACTICE GUIDELINES | INFLAMMATORY-BOWEL-DISEASE | THERAPEUTIC-EFFICACY | DOUBLE-BLIND | ITALIAN GROUP | PHARMACOLOGY & PHARMACY
Journal Article
Journal of Aerosol Medicine and Pulmonary Drug Delivery, ISSN 1941-2711, 06/2018, Volume 31, Issue 3, pp. 182 - 190
Background: Breath-actuated inhalers (BAIs) eliminate the need for hand-breath coordination required of pressurized metered-dose inhalers (MDIs). This...
Beclomethasone-17-monopropionate | Breath-actuated inhaler | Bioequivalence | Beclomethasone dipropionate | Dose proportionality | Metered-dose inhaler | Pharmacokinetics | breath-actuated inhaler | VOLUNTEERS | INHALATION | beclomethasone-17-monopropionate | INTRANASAL | BIOAVAILABILITY | metered-dose inhaler | THERAPY | RESPIRATORY SYSTEM | DISEASE | pharmacokinetics | ASTHMA | DEVICES | beclomethasone dipropionate | bioequivalence | dose proportionality | Beclomethasone - administration & dosage | Beclomethasone - pharmacokinetics | Humans | Middle Aged | Administration, Inhalation | Male | Healthy Volunteers | Cross-Over Studies | Young Adult | Beclomethasone - analogs & derivatives | Adolescent | Metered Dose Inhalers | Adult | Female | Nebulizers and Vaporizers | Physical examinations | Particle size | Substance abuse treatment | Parameters | Radioactive half-life | Pharmacology | Bioavailability | FDA approval | Inhalation | Asthma | Laboratory tests | Confidence intervals | Birth control | Bone morphogenetic proteins | Product development | Respiration | Inhalers | Drug dosages | Pharmaceuticals
Beclomethasone-17-monopropionate | Breath-actuated inhaler | Bioequivalence | Beclomethasone dipropionate | Dose proportionality | Metered-dose inhaler | Pharmacokinetics | breath-actuated inhaler | VOLUNTEERS | INHALATION | beclomethasone-17-monopropionate | INTRANASAL | BIOAVAILABILITY | metered-dose inhaler | THERAPY | RESPIRATORY SYSTEM | DISEASE | pharmacokinetics | ASTHMA | DEVICES | beclomethasone dipropionate | bioequivalence | dose proportionality | Beclomethasone - administration & dosage | Beclomethasone - pharmacokinetics | Humans | Middle Aged | Administration, Inhalation | Male | Healthy Volunteers | Cross-Over Studies | Young Adult | Beclomethasone - analogs & derivatives | Adolescent | Metered Dose Inhalers | Adult | Female | Nebulizers and Vaporizers | Physical examinations | Particle size | Substance abuse treatment | Parameters | Radioactive half-life | Pharmacology | Bioavailability | FDA approval | Inhalation | Asthma | Laboratory tests | Confidence intervals | Birth control | Bone morphogenetic proteins | Product development | Respiration | Inhalers | Drug dosages | Pharmaceuticals
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 07/2007, Volume 26, Issue 1, pp. 21 - 29
Summary Background Beclomethasone dipropionate (BDP) is a second‐generation steroid with topical effects and minimal systemic activity for patients with...
3 MG | MULTICENTER | SODIUM-PHOSPHATE ENEMAS | PROCTITIS | THERAPEUTIC-EFFICACY | DISEASE | TOPICAL TREATMENT | BUDESONIDE | PHARMACOLOGY & PHARMACY | MESALAZINE | GASTROENTEROLOGY & HEPATOLOGY | Beclomethasone - economics | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Humans | Anti-Inflammatory Agents - therapeutic use | Mesalamine - therapeutic use | Administration, Rectal | Female | Male | Treatment Outcome | Beclomethasone - therapeutic use | Mesalamine - economics | Beclomethasone dipropionate | Antiasthmatic agents | Mesalamine | Analysis | Ulcerative colitis
3 MG | MULTICENTER | SODIUM-PHOSPHATE ENEMAS | PROCTITIS | THERAPEUTIC-EFFICACY | DISEASE | TOPICAL TREATMENT | BUDESONIDE | PHARMACOLOGY & PHARMACY | MESALAZINE | GASTROENTEROLOGY & HEPATOLOGY | Beclomethasone - economics | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Humans | Anti-Inflammatory Agents - therapeutic use | Mesalamine - therapeutic use | Administration, Rectal | Female | Male | Treatment Outcome | Beclomethasone - therapeutic use | Mesalamine - economics | Beclomethasone dipropionate | Antiasthmatic agents | Mesalamine | Analysis | Ulcerative colitis
Journal Article
Environmental Science & Technology, ISSN 0013-936X, 08/2013, Volume 47, Issue 16, pp. 9487 - 9495
Pharmaceuticals present in the aquatic environment could adversely affect aquatic organisms. Synthetic glucocorticoids (GC) are used in large quantities as...
ENVIRONMENTAL SCIENCES | DEXAMETHASONE | RAINBOW-TROUT | ENGINEERING, ENVIRONMENTAL | FISH | RECEPTOR | CORTICOSTEROIDS | IDENTIFICATION | PIMEPHALES-PROMELAS | EXPRESSION | SALMO-TRUTTA-L | CORTISOL | Hypothalamo-Hypophyseal System - drug effects | Beclomethasone - administration & dosage | Glucocorticoids - administration & dosage | Beclomethasone - toxicity | Male | Vitellogenesis - drug effects | Sex Characteristics | Cyprinidae - metabolism | Blood Glucose - drug effects | Animals | Lymphocyte Count | Female | Glucocorticoids - toxicity
ENVIRONMENTAL SCIENCES | DEXAMETHASONE | RAINBOW-TROUT | ENGINEERING, ENVIRONMENTAL | FISH | RECEPTOR | CORTICOSTEROIDS | IDENTIFICATION | PIMEPHALES-PROMELAS | EXPRESSION | SALMO-TRUTTA-L | CORTISOL | Hypothalamo-Hypophyseal System - drug effects | Beclomethasone - administration & dosage | Glucocorticoids - administration & dosage | Beclomethasone - toxicity | Male | Vitellogenesis - drug effects | Sex Characteristics | Cyprinidae - metabolism | Blood Glucose - drug effects | Animals | Lymphocyte Count | Female | Glucocorticoids - toxicity
Journal Article
Tropical Journal of Pharmaceutical Research, ISSN 1596-5996, 01/2015, Volume 14, Issue 1, pp. 15 - 20
Purpose: To perform stability studies on a nanoemulsion formulation containing beclomethasone dipropionate (BD) and prepared by spontaneous emulsification...
Shelf-life | Viscosity | Accelerated stability | Refractive index | Nanoemulsion | Beclomethasone dipropionate | Conductivity | PHARMACOLOGY & PHARMACY | EMULSIONS
Shelf-life | Viscosity | Accelerated stability | Refractive index | Nanoemulsion | Beclomethasone dipropionate | Conductivity | PHARMACOLOGY & PHARMACY | EMULSIONS
Journal Article
Powder Technology, ISSN 0032-5910, 02/2017, Volume 308, pp. 200 - 205
Oral beclomethasone dipropionate (BDP) has been extensively studied in the management of ulcerative colitis in clinical practice in recently years. However,...
Subcritical water | Nanoparticles | Beclomethasone dipropionate | Green solvent | Green route | ULCERATIVE-COLITIS | EXCIPIENTS | RELEASE | INHALER | ANTISOLVENT PRECIPITATION | SOLUBILITY | MIXTURES | ENGINEERING, CHEMICAL | IN-VITRO | PHOSPHOLIPID NANOMICELLES | MICRONIZATION | Precipitation (Meteorology) | Polyols | Ulcerative colitis | Steroids | Yuan (China) | Powders | Surface active agents | Polyethylene glycol
Subcritical water | Nanoparticles | Beclomethasone dipropionate | Green solvent | Green route | ULCERATIVE-COLITIS | EXCIPIENTS | RELEASE | INHALER | ANTISOLVENT PRECIPITATION | SOLUBILITY | MIXTURES | ENGINEERING, CHEMICAL | IN-VITRO | PHOSPHOLIPID NANOMICELLES | MICRONIZATION | Precipitation (Meteorology) | Polyols | Ulcerative colitis | Steroids | Yuan (China) | Powders | Surface active agents | Polyethylene glycol
Journal Article
American Journal of Gastroenterology, ISSN 0002-9270, 05/2015, Volume 110, Issue 5, pp. 708 - 715
OBJECTIVES: Double-blind study comparing efficacy and safety of the topically acting corticosteroid beclomethasone dipropionate (BDP) to prednisone (PD) in...
CURRENT MANAGEMENT | UNDERESTIMATES CORTISOL SUPPRESSION | EVIDENCE-BASED CONSENSUS | THERAPY | BECLOMETASONE DIPROPIONATE | CROHNS-DISEASE | METABOLISM | BUDESONIDE | GASTROENTEROLOGY & HEPATOLOGY | 5-AMINOSALICYLIC ACID | Severity of Illness Index | Beclomethasone - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Humans | Middle Aged | Male | Young Adult | Anti-Inflammatory Agents - adverse effects | Adolescent | Intention to Treat Analysis | Beclomethasone - adverse effects | Adult | Anti-Inflammatory Agents - administration & dosage | Female | Aged | Colitis, Ulcerative - drug therapy | Hydrocortisone - blood | Tablets, Enteric-Coated
CURRENT MANAGEMENT | UNDERESTIMATES CORTISOL SUPPRESSION | EVIDENCE-BASED CONSENSUS | THERAPY | BECLOMETASONE DIPROPIONATE | CROHNS-DISEASE | METABOLISM | BUDESONIDE | GASTROENTEROLOGY & HEPATOLOGY | 5-AMINOSALICYLIC ACID | Severity of Illness Index | Beclomethasone - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Humans | Middle Aged | Male | Young Adult | Anti-Inflammatory Agents - adverse effects | Adolescent | Intention to Treat Analysis | Beclomethasone - adverse effects | Adult | Anti-Inflammatory Agents - administration & dosage | Female | Aged | Colitis, Ulcerative - drug therapy | Hydrocortisone - blood | Tablets, Enteric-Coated
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 10/2012, Volume 436, Issue 1-2, pp. 1 - 9
The engineering ultrafine drug particles of beclomethasone dipropionate for dry powder inhalation administration were prepared by combining microfluidic...
Beclomethasone dipropionate | Homogenization | Spray drying | T-junction microchannel | Dry powder inhalation | CRYSTALLIZATION | REACTIVE PRECIPITATION | SIZE | MICROCHANNELS | CARRIER | DELIVERY | SOLID LIPID NANOPARTICLES | MICRONIZATION | PHARMACOLOGY & PHARMACY | MORPHOLOGY | Particle Size | Beclomethasone - administration & dosage | Dry Powder Inhalers | Microscopy, Electron, Scanning | Chemistry, Pharmaceutical - methods | X-Ray Diffraction | Administration, Inhalation | Drug Compounding | Anti-Asthmatic Agents - administration & dosage | Beclomethasone - chemistry | Spectroscopy, Fourier Transform Infrared | Anti-Asthmatic Agents - chemistry | Drugs | Drug delivery systems | Antiasthmatic agents | Precipitation (Meteorology) | Microfluidics | Vehicles | Steroids
Beclomethasone dipropionate | Homogenization | Spray drying | T-junction microchannel | Dry powder inhalation | CRYSTALLIZATION | REACTIVE PRECIPITATION | SIZE | MICROCHANNELS | CARRIER | DELIVERY | SOLID LIPID NANOPARTICLES | MICRONIZATION | PHARMACOLOGY & PHARMACY | MORPHOLOGY | Particle Size | Beclomethasone - administration & dosage | Dry Powder Inhalers | Microscopy, Electron, Scanning | Chemistry, Pharmaceutical - methods | X-Ray Diffraction | Administration, Inhalation | Drug Compounding | Anti-Asthmatic Agents - administration & dosage | Beclomethasone - chemistry | Spectroscopy, Fourier Transform Infrared | Anti-Asthmatic Agents - chemistry | Drugs | Drug delivery systems | Antiasthmatic agents | Precipitation (Meteorology) | Microfluidics | Vehicles | Steroids
Journal Article
International Journal of COPD, ISSN 1176-9106, 10/2017, Volume 12, pp. 2917 - 2928
The goals of COPD therapy are to prevent and control symptoms, reduce the frequency and severity of exacerbations, and improve exercise tolerance. The triple...
Beclomethasone dipropionate | Formoterol fumarate and glycopyrronium bromide | COPD | Inhaled triple therapy | INHALED CORTICOSTEROIDS | LUNG-FUNCTION | SALMETEROL/FLUTICASONE | formoterol fumarate and glycopyrronium bromide | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | inhaled triple therapy | PARALLEL-GROUP | DOUBLE-BLIND | EXACERBATIONS | TIOTROPIUM | beclomethasone dipropionate | FLUTICASONE | BRONCHODILATORS | Glucocorticoids - administration & dosage | Bronchodilator Agents - administration & dosage | Humans | Muscarinic Antagonists - adverse effects | Pulmonary Disease, Chronic Obstructive - physiopathology | Exercise Tolerance - drug effects | Recovery of Function | Forced Expiratory Volume | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Bronchodilator Agents - adverse effects | Glucocorticoids - adverse effects | Glycopyrrolate - adverse effects | Pulmonary Disease, Chronic Obstructive - diagnosis | Beclomethasone - administration & dosage | Risk Factors | Formoterol Fumarate - adverse effects | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Evidence-Based Medicine | Disease Progression | Muscarinic Antagonists - administration & dosage | Glycopyrrolate - administration & dosage | Lung - drug effects | Beclomethasone - adverse effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Drug Combinations | Nebulizers and Vaporizers | Formoterol Fumarate - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Formoterol | Dosage and administration | Glycopyrrolate | Drug therapy, Combination | Research | Drug therapy | Risk factors | Formoterol Fumarate and Glycopyrronium Bromide | Beclomethasone Diproprionate
Beclomethasone dipropionate | Formoterol fumarate and glycopyrronium bromide | COPD | Inhaled triple therapy | INHALED CORTICOSTEROIDS | LUNG-FUNCTION | SALMETEROL/FLUTICASONE | formoterol fumarate and glycopyrronium bromide | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | inhaled triple therapy | PARALLEL-GROUP | DOUBLE-BLIND | EXACERBATIONS | TIOTROPIUM | beclomethasone dipropionate | FLUTICASONE | BRONCHODILATORS | Glucocorticoids - administration & dosage | Bronchodilator Agents - administration & dosage | Humans | Muscarinic Antagonists - adverse effects | Pulmonary Disease, Chronic Obstructive - physiopathology | Exercise Tolerance - drug effects | Recovery of Function | Forced Expiratory Volume | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Bronchodilator Agents - adverse effects | Glucocorticoids - adverse effects | Glycopyrrolate - adverse effects | Pulmonary Disease, Chronic Obstructive - diagnosis | Beclomethasone - administration & dosage | Risk Factors | Formoterol Fumarate - adverse effects | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Evidence-Based Medicine | Disease Progression | Muscarinic Antagonists - administration & dosage | Glycopyrrolate - administration & dosage | Lung - drug effects | Beclomethasone - adverse effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Drug Combinations | Nebulizers and Vaporizers | Formoterol Fumarate - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Formoterol | Dosage and administration | Glycopyrrolate | Drug therapy, Combination | Research | Drug therapy | Risk factors | Formoterol Fumarate and Glycopyrronium Bromide | Beclomethasone Diproprionate
Journal Article
Recenti progressi in medicina, 11/2017, Volume 108, Issue 11, p. 1
Anti-Asthmatic Agents - adverse effects | Beclomethasone - administration & dosage | Glucocorticoids - administration & dosage | Humans | Administration, Inhalation | Beclomethasone - adverse effects | Aerosol Propellants - chemistry | Anti-Asthmatic Agents - administration & dosage | Asthma - drug therapy | Glucocorticoids - adverse effects | Nebulizers and Vaporizers
Journal Article
AAPS PharmSciTech, ISSN 1530-9932, 5/2019, Volume 20, Issue 4, pp. 1 - 12
The current study is concerned with the development and characterization of mixed micelles intended for the dermal delivery of beclomethasone dipropionate,...
Biochemistry, general | Biotechnology | Biomedicine | in vivo histopathology | hydrogel | Pharmacy | beclomethasone dipropionate | mixed micelles | Pharmacology/Toxicology | dermal | DRUG | STABILITY | POLYMERIC NANOCARRIERS | BLOCK-COPOLYMER MICELLES | BIOAVAILABILITY | DELIVERY | ATOPIC-DERMATITIS | IN-VITRO CHARACTERIZATION | VIVO ESTIMATION | PHARMACOLOGY & PHARMACY | Corticosteroids | Drugstores | Dielectric films | Patient compliance | Transdermal medication | Thin films | Methylcellulose | Surface active agents | Atopic dermatitis | Analysis | Beclomethasone dipropionate | Histochemistry | Steroids
Biochemistry, general | Biotechnology | Biomedicine | in vivo histopathology | hydrogel | Pharmacy | beclomethasone dipropionate | mixed micelles | Pharmacology/Toxicology | dermal | DRUG | STABILITY | POLYMERIC NANOCARRIERS | BLOCK-COPOLYMER MICELLES | BIOAVAILABILITY | DELIVERY | ATOPIC-DERMATITIS | IN-VITRO CHARACTERIZATION | VIVO ESTIMATION | PHARMACOLOGY & PHARMACY | Corticosteroids | Drugstores | Dielectric films | Patient compliance | Transdermal medication | Thin films | Methylcellulose | Surface active agents | Atopic dermatitis | Analysis | Beclomethasone dipropionate | Histochemistry | Steroids
Journal Article